Ask AI

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

Enhance your understanding of adjuvant CDK4/6 inhibitors currently used to manage high-risk HR-positive/HER2-negative early breast cancer (EBC) to optimally integrate pharmacist-led strategies into patient care through a certified podcast and on-demand webcast, as well as an expert-written ClinicalThought commentary and downloadable slides.

Share

Program Content

Events

Activities

Adjuvant CDK46i Optimization
Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2026

Expires: March 12, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Lilly.

Lilly